Targets › PVRL4
3 programs from 2 companies in 6 trials: 5 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.; FUNCTION: (Microbial infection) Acts as a receptor for measles virus. (UniProt, Q96NY8)
Open in Phaseline: the race on PVRL4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fudan University | SHR-A2102 Nectin4-directed antibody-drug conjugate | PVRL4 | Phase 2 | Triple-negative Breast Cancer; Pancreatic Cancer; Advanced Breast Cancer | Dec 2026 |
| Fudan University | 9MW2821 Nectin4-directed antibody-drug conjugate | PVRL4 | Phase 2 | Advanced Breast Cancer | Sep 2027 |
| Eastern Hepatobiliary Surgery Hospital | Super Hi-TCR-T cells Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP | PVRL4, KLRC1, TROP2, B7H3, GPC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Jan 2028 |
Pancreatic Cancer (2) Advanced Breast Cancer (2) Triple-negative Breast Cancer (1) Advanced Hepatocellular Carcinoma (HCC) (1)
mixed (2), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.